494 related articles for article (PubMed ID: 9614559)
1. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
[TBL] [Abstract][Full Text] [Related]
2. Partial regression, yet incomplete eradication of mammary tumors in transgenic mice by retrovirally mediated HSVtk transfer 'in vivo'.
Sacco MG; Benedetti S; Duflot-Dancer A; Mesnil M; Bagnasco L; Strina D; Fasolo V; Villa A; Macchi P; Faranda S; Vezzoni P; Finocchiaro G
Gene Ther; 1996 Dec; 3(12):1151-6. PubMed ID: 8986442
[TBL] [Abstract][Full Text] [Related]
3. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
4. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
Jacquemart IC; Springs AE; Chen WY
Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
[TBL] [Abstract][Full Text] [Related]
5. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
[TBL] [Abstract][Full Text] [Related]
6. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
7. Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development.
Jolicoeur P; Bouchard L; Guimond A; Ste-Marie M; Hanna Z; Dievart A
Biochem Soc Symp; 1998; 63():159-65. PubMed ID: 9513720
[TBL] [Abstract][Full Text] [Related]
8. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
[TBL] [Abstract][Full Text] [Related]
9. PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas.
Trimble MS; Xin JH; Guy CT; Muller WJ; Hassell JA
Oncogene; 1993 Nov; 8(11):3037-42. PubMed ID: 7692372
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Notch1 in the development of mouse mammary tumors.
Diévart A; Beaulieu N; Jolicoeur P
Oncogene; 1999 Oct; 18(44):5973-81. PubMed ID: 10557086
[TBL] [Abstract][Full Text] [Related]
12. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Zinser GM; Welsh J
Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467
[TBL] [Abstract][Full Text] [Related]
15. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice.
Krane IM; Leder P
Oncogene; 1996 Apr; 12(8):1781-8. PubMed ID: 8622899
[TBL] [Abstract][Full Text] [Related]
16. Antisense downregulation of a mouse mammary tumor virus activated protooncogene in mouse mammary tumor cells reverses the malignant phenotype.
Li YX; Papkoff J; Sarkar NH
Virology; 1999 Mar; 255(1):138-49. PubMed ID: 10049829
[TBL] [Abstract][Full Text] [Related]
17. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice.
Kitsberg DI; Leder P
Oncogene; 1996 Dec; 13(12):2507-15. PubMed ID: 9000125
[TBL] [Abstract][Full Text] [Related]
18. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors.
Morrison BW; Leder P
Oncogene; 1994 Dec; 9(12):3417-26. PubMed ID: 7970700
[TBL] [Abstract][Full Text] [Related]
19. Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu.
Hewitt SC; Bocchinfuso WP; Zhai J; Harrell C; Koonce L; Clark J; Myers P; Korach KS
Cancer Res; 2002 May; 62(10):2798-805. PubMed ID: 12019156
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
